CRISPR THERAPEUTICS AG Net Income (Loss) Available to Common Stockholders, Basic
CRISPR THERAPEUTICS AG (CRSP) reported Net Income (Loss) Available to Common Stockholders, Basic of $66.86 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-12.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2020-02-12
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was $30.54M.
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for the quarter ending 2019-09-30 was $138.42M.
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was -$47.59M.
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$50.71M.
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for fiscal 2019 was $66.86M.
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for fiscal 2018 was -$164.98M.
- CRISPR THERAPEUTICS AG net income (loss) available to common stockholders, basic for fiscal 2017 was -$68.36M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2019-12-31 | $30.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $168.97M derived: sum of 2 quarters · filed 2020-02-12 | $66.86M 10-K · filed 2020-02-12 | |
| 2019-09-30 | $138.42M 10-Q · filed 2019-10-28 | $36.32M 10-Q · filed 2019-10-28 | ||
| 2018-12-31 | -$47.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | -$98.30M derived: sum of 2 quarters · filed 2020-02-12 | -$164.98M 10-K · filed 2020-02-12 | |
| 2018-09-30 | -$50.71M 10-Q · filed 2019-10-28 | -$117.39M 10-Q · filed 2019-10-28 | ||
| 2017-12-31 | -$68.36M 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |